Literature DB >> 12842902

Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3.

Robert Rauchenberger1, Eric Borges, Elisabeth Thomassen-Wolf, Eran Rom, Rivka Adar, Yael Yaniv, Michael Malka, Irina Chumakov, Sarit Kotzer, Dalia Resnitzky, Achim Knappik, Silke Reiffert, Josef Prassler, Karin Jury, Dirk Waldherr, Susanne Bauer, Titus Kretzschmar, Avner Yayon, Christine Rothe.   

Abstract

The human combinatorial antibody library Fab 1 (HuCAL-Fab 1) was generated by transferring the heavy and light chain variable regions from the previously constructed single-chain Fv library (Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G., Hoess, A., Wölle, J., Plückthun, A., and Virnekäs, B. (2000) J. Mol. Biol. 296, 57-86), diversified in both complementarity-determining regions 3 into a novel Fab display vector, yielding 2.1 x 10(10) different antibody fragments. The modularity has been retained in the Fab display and screening plasmids, ensuring rapid conversion into various antibody formats as well as antibody optimization using prebuilt maturation cassettes. HuCAL-Fab 1 was challenged against the human fibroblast growth factor receptor 3, a potential therapeutic antibody target, against which, to the best of our knowledge, no functional antibodies could be generated so far. A unique screening mode was designed utilizing recombinant functional proteins and cell lines differentially expressing fibroblast growth factor receptor isoforms diversified in expression and receptor dependence. Specific Fab fragments with subnanomolar affinities were isolated by selection without any maturation steps as determined by fluorescence flow cytometry. Some of the selected Fab fragments completely inhibit target-mediated cell proliferation, rendering them the first monoclonal antibodies against fibroblast growth factor receptors having significant function blocking activity. This study validates HuCAL-Fab 1 as a valuable source for the generation of target-specific antibodies for therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12842902     DOI: 10.1074/jbc.M303164200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

Review 1.  Mining human antibody repertoires.

Authors:  Roger R Beerli; Christoph Rader
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

Review 2.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

Review 3.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

4.  APEx 2-hybrid, a quantitative protein-protein interaction assay for antibody discovery and engineering.

Authors:  Ki Jun Jeong; Min Jeong Seo; Brent L Iverson; George Georgiou
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-09       Impact factor: 11.205

Review 5.  FGFR3-related dwarfism and cell signaling.

Authors:  Daisuke Harada; Yoshitaka Yamanaka; Koso Ueda; Hiroyuki Tanaka; Yoshiki Seino
Journal:  J Bone Miner Metab       Date:  2008-12-09       Impact factor: 2.626

6.  A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties.

Authors:  Thomas Tiller; Ingrid Schuster; Dorothée Deppe; Katja Siegers; Ralf Strohner; Tanja Herrmann; Marion Berenguer; Dominique Poujol; Jennifer Stehle; Yvonne Stark; Martin Heßling; Daniela Daubert; Karin Felderer; Stefan Kaden; Johanna Kölln; Markus Enzelberger; Stefanie Urlinger
Journal:  MAbs       Date:  2013-04-09       Impact factor: 5.857

Review 7.  Achondroplasia: Development, pathogenesis, and therapy.

Authors:  David M Ornitz; Laurence Legeai-Mallet
Journal:  Dev Dyn       Date:  2017-03-02       Impact factor: 3.780

Review 8.  Integrating high-throughput screening and sequencing for monoclonal antibody discovery and engineering.

Authors:  Cristina Parola; Daniel Neumeier; Sai T Reddy
Journal:  Immunology       Date:  2017-10-30       Impact factor: 7.397

9.  Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth.

Authors:  David Kiewlich; Jianhuan Zhang; Cynthia Gross; Wei Xia; Brent Larsen; Ronald R Cobb; Sandra Biroc; Jian-Ming Gu; Takashi Sato; David R Light; Tara Heitner; Joerg Willuda; David Vogel; Felipe Monteclaro; Andrzej Citkowicz; Steve R Roffler; Deborah A Zajchowski
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

10.  Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naïve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth.

Authors:  Elena Gustchina; John M Louis; Christian Frisch; Francisco Ylera; Annette Lechner; Carole A Bewley; G Marius Clore
Journal:  Virology       Date:  2009-08-19       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.